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Economic analysis of life-saving investments in both the public and private sectors has 
the potential to dramatically improve longevity and the quality of life, but only if the analyses on 
which decisions are based are done well. In this paper we analyze a dataset that provides 
information on the content and quality of journal articles that measure the cost-effectiveness of 
life-saving investments. Our study is the first to provide a detailed multivariate analysis of 
factors affecting objective measures of quality. We also explore whether a series of 
recommendations by an expert panel convened by the U.S. Public Health Service affect the way 
analyses of specific life-saving investments are done.  
 
Our results suggest that four factors are positively correlated with an index we construct 
to measure analytical quality: 1. having at least one author affiliated with a university; 2. 
publication in a journal that has experience in publishing these analyses; 3. if the life-saving 
investment is located in the U.S., and 4. if the analysis considers a measure of social costs or 
benefits. Somewhat surprisingly, a study’s funding source and whether it is affiliated with 
industry are not significantly correlated with the quality index. Finally, neither time nor the panel 
guidelines had an impact on the index.  
         1
What Affects the Quality of Economic Analysis for Life-Saving Investments? 
 




Governments around the world are experiencing increasing demands to address health, 
safety, and environmental concerns. At the same time, political leaders are seeing a need to use 
good science and economics in making policy choices aimed at saving lives and improving the 
quality of life.
1 Partly in response to this need, policy analysts are relying more heavily on two 
tools widely embraced by applied economists: cost-benefit analysis and cost-effectiveness 
analysis. 
Cost-benefit analysis attempts to measure the costs and benefits of a decision and to 
monetize them where possible.
2 Cost-effectiveness analysis typically monetizes costs, but leaves 
benefits in terms of other units, such as statistical lives or quality adjusted life years.
3  It is 
widely recognized that cost-benefit analysis and cost-effectiveness analysis can play a critical 
role in informing decisions aimed at promoting pubic health and saving lives.
4 
The potential for economic analysis to improve decision making was one of the main 
motivations for requiring such analysis for U.S. federal regulations.
5 Every president since 
Reagan has required executive regulatory agencies to perform benefit-cost analyses for most 
regulations estimated to impose annual costs of over $100 million.
6  These regulatory impact 
analyses inform important government decisions, such as whether to require airbags in vehicles 
or reduce particulate emissions. Such decisions are estimated to result in roughly two hundred 
billion dollars of expenditures annually.
7 
In some cases, economic analyses of public policy decisions have had a marked impact 
on health-related issues. For example, the decision to curtail the use of chlorofluorocarbons and 
                                                 
1 See, e.g., Tony Blair (2005). 
2 See, e.g., Arrow et al. (1996). 
3 See Lave (1981) and Russell et al. (1996). 
4 For an insightful evaluation of the value of medical research, see Murphy and Topel (2003). For an excellent 
overview of the potential to save lives and/or reduce costs, see Morrall (2003). 
5 See, e.g., Litan and Nordhaus (1983). For an insightful assessment of the importance of analysis, see Farrow 
(1991).  
6 See Smith (1984) and Viscusi (1996) for illuminating discussions on the efforts to reform regulation.. 
7 See, e.g. Arrow et al. (1996).         2
the decision to phase out lead from gasoline were both influenced by the careful application of 
cost-benefit analysis.
8 And cost-effectiveness analysis played an important role in the decision to 
implement a market-based approach for reducing sulfur dioxide emissions.
9  
Because of the potential importance of cost-benefit analysis and cost-effectiveness 
analysis in informing policy decisions, a number of organizations have issued guidelines that 
researchers and government officials may want to follow. For example, the U.S. Office of 
Management and Budget issued “best practice” guidelines for performing regulatory impact 
analysis. The aim was to improve the quality of regulatory analysis and help standardize the 
measurement and reporting of costs and benefits.
10 Similarly, the U.S. Public Health Service 
organized the Panel on Cost-Effectiveness in Health and Medicine to establish protocols for 
analyzing the cost-effectiveness of health interventions.
11 The panel offered recommendations 
directed toward both authors and users of cost-effectiveness analyses for improving the quality 
as well as the comparability of cost-effectiveness analyses.
12  
Economic analysis of life-saving investments in both the public and private sectors has 
the potential to dramatically improve longevity and the quality of life, but only if the analyses on 
which decisions are based are done well. Currently, one of the key impediments to the effective 
use of such analyses is the lack of quality and comparability with other studies.
13  
There are three basic approaches to assessing the quality of such analyses. One is to 
conduct case studies of particular examples.
14 The main advantage of this approach is that 
detailed analysis of individual cases can highlight the strengths and weaknesses of the data, 
assumptions, and underlying models. A major weakness is that the analytical methods are not 
easily generalized and the results are not easily replicated. Furthermore, reasonable people may 
                                                 
8 See Nichols (1997) on the lead phase out and Hammitt (1997) on chlorofluorocarbons. See also Sunstein (2002) 
for a good overview. For an insightful study of whether regulators make rational decisions, see Viscusi and 
Hamilton (1999). 
9 See, e.g., Schmalensee et al. (1998) and Stavins (1998).  
10Office of Management and Budget (2003). In 2003, OMB issued circular A-4, which refines the “best practices” 
recommendations of 1996. 
11 Panel members included 13 scientists and scholars with expertise in cost-effectiveness analysis, clinical medicine, 
ethics, and health outcomes measurement. The panel met 11 times between 1993 and 1996. 
12 The major panel recommendations appeared in a three-part Consensus Statement published in the Journal of the 
American Medical Association in 1996 (Russell, et al. 1996) and in a book (Gold, et al. 1996). These 
recommendations broadly apply to all cost-effectiveness analyses of interventions designed to improve health. As 
described in Russell et al. (1996), the panel’s focus was on “policy decisions and resource allocation at a broad 
level.” 
13 See, e.g., Russell et al. (1996).  Even if cost-effectiveness analyses are of high-quality, however, there are other 
barriers to their use. For instance, political considerations may impede efficient decisions.         3
disagree about the relative quality of analyses because of the highly subjective nature of the case 
study approach. A second approach uses estimates of a key parameter, such as net benefits or 
cost effectiveness, from studies done prior to and after the implementation of a policy. The idea 
is that the estimate done after a study may provide a better measure of the actual impact of a 
policy.
15 A third approach uses more objective measures, often those recommended by experts, 
to judge the quality of an analysis. An advantage of this approach is that it is easily generalized 
and replicated and allows comparison of a large and a wide range of different analyses. A 
drawback is that satisfying all of the objective measures recommended by experts does not 
necessarily imply a high-quality analysis. Thus, any objective measure is likely to be an 
imperfect proxy for quality. Nonetheless, using objective measures to judge quality is perhaps 
the best way to draw conclusions based on hundreds of disparate analyses. 
Few studies have used regression analysis to address factors affecting analytical quality 
and whether economic analysis has actually improved over time. In this paper, we analyze a 
dataset that provides information on the content and quality of journal articles that measure the 
cost-effectiveness of life-saving investments. Our study is the first to provide a detailed 
multivariate analysis of factors affecting objective measures of quality. We also explore whether 
the recommendations by the expert panel convened by the U.S. Public Health Service affect the 
way analyses of specific life-saving investments are done.  
Our results suggest that four factors are positively correlated with an index we construct 
to measure analytical quality: 1. having at least one author affiliated with a university; 2. 
publication in a journal that has experience in publishing these analyses; 3. if the life-saving 
investment is located in the U.S., and 4. if the analysis consider a measure of social costs or 
benefits. We find that a study’s funding source and whether it is affiliated with industry are not 
significantly correlated with the quality index. Finally, neither time nor the panel guidelines had 
an impact on the index. 
                                                                                                                                                             
14 See, e.g., Morgenstern (1997). 
15 See, e.g., Harrington et al. (2000). This approach poses a number of challenges from the standpoint of measuring 
quality. First, the quality of the analysis is contingent on the state of information available when the studies are 
done. Second, there is no reason to necessarily believe estimates done after the fact are necessarily more accurate, 
even though they presumably rely on more recent information. Third, there are relatively few studies of this kind up 
to this point, and they are costly to do. All of these problems can be remedied to varying degrees. For example, to 
address the information problem, one could use information markets. Indeed, these markets provide yet another way 
to make assessments of quality at a given point in time or over time. See, for example, Abramowicz (2004). The 
problem is that such markets are not widely available at this point.         4
The paper is organized as follows. Section 1 offers background information on research 
regarding the quality of cost-benefit analysis and cost-effectiveness analysis. Section 2 reviews 
our basic approach and summarizes the data. Section 3 presents our empirical tests and describes 




Only in the last decade have scholars systematically examined the quality of cost-benefit 
and cost-effectiveness analyses.  This research has focused primarily on cost-effectiveness 
analyses of health interventions and cost-benefit analysis of economic regulations. Both types of 
studies have identified factors that could affect analytical quality. Some studies find evidence 
that the quality of analyses has improved over time while others find improvements in certain 
areas but no overall improvement. Studies of the regulatory impact analysis literature have used 
multivariate analysis to determine the factors affecting quality while simultaneously controlling 
for other study factors. Studies focusing on the quality of cost-effectiveness analyses (CEAs), 
however, have not.  Here we present what is known about the factors affecting analytical quality 
and whether it has improved over time.  
Studies focusing on the medical economics literature have identified a number of factors 
that may affect the quality of a cost-effectiveness analysis.
16 Udvarhelyi et al. (1992) find that 
articles in general medical journals are more likely to use analytic methods appropriately than 
articles in general surgical or medical subspecialty journals. Gerard et al. (1999) find great 
variation in analytical quality among published cost-effectiveness analyses, but find that analyses 
appearing in specialist medical journals tend to be worse than those in more general medical 
journals. Similarly, Neumann et al. (2000) find that a journal’s experience in publishing cost-
effectiveness analyses is more important than the type of journal in explaining quality, although 
general medical and surgical journals tend to have better reporting practices, conduct certain 
kinds of sensitivity analyses, and discuss ethical implications better than sub-specialty journals.  
Using a larger dataset, Neumann et al. (2005) find that quality increases with a journal’s 
experience in publishing cost-effectiveness analyses, but that that industry funding does not 
                                                 
16 Frequently the analyses measure the cost per quality adjusted life year. Such analyses are sometimes referred to as 
cost-utility analyses.         5
affect analytical quality. Using bivariate analysis, these studies suggest that cost-effectiveness 
analyses have improved over time and that industry funding does not affect the quality of an 
analysis.
17 
Studies focusing on the quality of regulatory impact analyses have also identified factors 
that likely affect quality. Hahn et al. (2000) reviewed 48 major environmental, health, and safety 
regulations and their associated regulatory impact analyses conducted by United States 
government agencies between 1996 and 1999. The authors use a number of objective measures 
of quality such as whether the analysis provides a point estimate or a range estimate of net 
benefits and whether it uses a discount rate.
18 The study suggests several reasons for a relatively 
low level of quality, including resource constraints and the possibility that an agency may not 
want interested parties to know that the costs of a regulation exceed the benefits. Hahn and 
Dudley (2004) use multivariate analysis to review 74 regulatory impact analyses of health, 
environmental, and safety regulations spanning the Reagan, first Bush, and Clinton 
administrations. The authors find that measures of quality are generally unrelated to key factors 
such as the size of the regulation and under which administration it was implemented. They do 
not address the effects of funding source on quality because the government funds regulatory 
impact analyses.
19  
Studies of the health and medical cost-effectiveness analysis literature have also 
examined whether analytical quality has improved over time, but generally do not control for 
other factors.  Udvarhelyi et al. (1992) find no significant improvement in the quality of cost-
effectiveness analyses between 1978 and 1987. Chapman et al. (2000) find some evidence 
suggesting that quality has improved over time for some factors, such as discounting. This 
suggests that quality, as measured by these criteria, has improved over time. Neumann et al. 
(2000) find that the number of cost-effectiveness analyses published annually has increased over 
                                                 
17 One study, Neumann et al. (2000), does include some multivariate analysis. This analysis, however, did not 
control for the myriad factors that could affect quality. 
18 In Hahn et al. (2000) and Hahn and Dudley (2004), scoring involved a primary scorer and a second individual 
who validated the findings of the first scorer. The primary scorer used the regulatory impact analysis to evaluate 
each item on the scorecard. The second researcher validated the first researcher’s findings by reviewing the analysis 
and the completed scorecard. If the findings of the two researchers differed for any part of the scorecard, the 
researchers resolved the differences by discussion. 
19 While regulatory impact analyses are usually funded by the government, they are sometimes carried out with the 
assistance of non-governmental organizations and the private sector. Hahn and Dudley (2004) does not examine the 
effect of author affiliation on analysis quality.         6
time and that the average quality of those analyses has improved slightly over time.
20 Neumann 
et al. (2005) find evidence that cost-effectiveness analysis quality seems to be improving, but 
emphasize that many studies still fail to follow recommended protocols. The authors also note an 
increased use of a 3% discount rate and a societal perspective after the Panel on Cost-
Effectiveness in Health and Medicine recommended them in 1996—measures that could make 
studies more easily compared to other studies and more useful for public policy.  
To our knowledge, only one study examines changes in the quality of regulatory impact 
analyses over time. Hahn and Dudley (2004) use a multivariate analysis and find that measures 
of quality are generally unrelated to the year in which a regulation is implemented. This result is 
similar to the findings of Udvarhelyi et al. (1992), but different from the findings of more recent 
analyses including Chapman et al. (2000), Neumann et al. (2000), and Neumann et al. (2005). 
One reason for the apparently conflicting results could be that the studies focusing on the cost-
effectiveness analysis literature do not generally use regression analysis while the study focusing 
on regulatory impact analyses does. It is possible that their results would evaporate upon 
controlling for other study and author factors. 
As noted, only the literature reviewing the quality of regulatory impact analyses has 
controlled for multiple factors that could affect the quality of analysis in a multivariate 
framework. It is also the only literature that has used a rigorous multivariate analysis to test 
whether “best practice” guidelines actually affect the quality of economic analysis.
21 As a result, 
it is still unclear what factors affect the quality of cost-effectiveness analyses and whether these 
analyses improved following the 1996 recommendations of the Panel on Cost-Effectiveness in 




Our analysis is based on data from the Cost-Effectiveness Analysis Registry, which is 
maintained by researchers at the Harvard School of Public Health (HSPH).
22 The registry, 
                                                 
20 In Neumann et al. (2000) and Neumann et al. (2005), a number of readers, all with masters or doctoral degree 
training in decision analysis and cost-effectiveness analysis, scored the cost-effectiveness analyses on a subjective, 
Likert scale ranging from 1 (low) to 7 (high). Scores were assigned based on overall study quality. Two readers 
independently read and scored each cost-effectiveness analysis. 
21 See Hahn and Dudley (2004) 
22 The CEA registry has been supported in the past by grant number R01 HS10919 from the Agency for Health Care         7
intended to be comprehensive, includes 533 cost-effectiveness analyses published in peer-
reviewed medical journals between 1976 and 2001.
23 The analyses fit into five main categories: 
health care, occupational or school-based, transportation, residential, and environmental.
24 The 
registry contains data on the methods used to estimate costs and effects as well as detailed 
information on the authors and analyses themselves.  Two trained readers independently 
reviewed each study, completed a data abstraction form, and then met to resolve any 
discrepancies in their ratings. 
Table 1 defines the measures of the cost-effectiveness analyses in the registry that we use 
in our analysis.  We use these variables in several ways.  First, we create dummy variables 
indicating whether the author included each of a number of recommended research methods in 
her cost-effectiveness analysis.  Second, we create two indices that count the number of these 
methods that the author included in her analysis.  We designed the first index, which we call the 
quality index, to measure basic analytical quality. It ranges from zero to four, depending on the 
number of a set of four particularly well-defined methods the author included: whether the author 
performed incremental analysis, stated the year of currency used in the cost estimates, performed 
sensitivity analyses,
25 and discounted costs and quality adjusted life years.
26  The four 
                                                                                                                                                             
Research and Quality and support from the Harvard Interfaculty Program for Health Systems Improvement.  It is 
currently supported by the National Library of Medicine, grant number GO8LM008413. Registry investigators 
attempted to include every cost-effectiveness analysis published between 1976 and 2001 that met specified criteria.  
The criteria include the following: the analysis must be written in English, have been published in a peer-reviewed 
medical journal (ruling out government reports), specifically use the measure “$/quality adjusted life year” (or some 
other currency), and include original quality adjusted life year measures (ruling out papers that do not provide 
original estimates). Harvard Center for Risk Analysis and Harvard School of Publish Health (2005). 
23 Our analysis uses cost-effectiveness analyses in the CEA registry written between 1992 and 2001. This 
encompasses the vast majority of analyses (484 of the 533 total analyses currently in the registry). 
24 The vast majority of the studies in the registry are in the health care category. There is a small number in each of 
the other categories. Health care studies cover a range of medical and health care interventions. An occupational/ 
school-based cost-effectiveness analysis might examine the effectiveness of a particular vaccine in the military or 
the effect of a school-based tobacco-use prevention program on teen smoking. A transportation analysis might study 
the effectiveness of air bags, seat belts, or laws against the use of cell phones while driving in preventing traffic 
fatalities. A residential analysis might examine the effectiveness of a tuberculosis screening process in long-term 
care facilities or the effectiveness of insecticide-treated bed nets in avoiding child mortality. 
25 The reliability of this measure may be affected by a slight change in the question asked by the registry team over 
time (in 1997 and subsequent cost-effectiveness analyses, it was different than for earlier analyses). In addition, the 
registry team was occasionally not clear if what a study did should qualify as sensitivity analysis. In general, readers 
were generous in determining whether the authors incorporated sensitivity analysis. 
26 We used the 0-4 index in our analysis of what determines analytical quality and the 0-8 index in our analysis of 
whether studies followed the 1996 panel recommendations. The index comprises fewer variables when we view 
quality as “analytical quality” as opposed to “adherence to the panel recommendations” because some of the 
recommendations have less to do with analytical quality and more to do with ensuring cost-effectiveness analysis 
comparability and imposing relatively arbitrary constraints (such as using a 3% discount rate and a societal 
perspective). We do not include performing model validation in the 0-4 index because of how loosely the variable         8
components of the quality index represent what we believe to be the bare minimum requirements 
for an analysis to be useful.
27 The second index, from zero to eight, includes all measures related 
to recommendations by the panel. We divide these recommendations into two types: those 
intended to improve empirical soundness and those intended to improve the comparability of 
analyses. We designed this index, which we call the panel index, to measure the compliance of 
cost-effectiveness analyses with recommended protocols—whether they are intended to improve 
empirical quality (such as the components in the quality index) or the comparability of disparate 
analyses.
28 In addition to the measures in the first index, it also includes whether the authors 
included probabilistic sensitivity analysis, model validation, a 3% discount rate, and a societal 
perspective.
29 Finally, we also use a subjective score of overall analysis quality (on a scale of 1 
(low) to 7 (high)), which the reader who catalogued the analysis for the database assigned. Table 
2 shows the means of these variables. 
The dataset also included other useful information: the journal in which the cost-
effectiveness analysis appeared, the year it was published, primary research funders, authors’ 
affiliations, authors’ perspective(s),
30 and the country or countries on which the study focused 
                                                                                                                                                             
was defined. As described in Table 1, when the registry team compiled data on validation, they characterized 
validation very generously; if the author compared modeling projections for disease progression to actual data 
(empirical work), contrasted results from different models, or even discussed “model validation,” they were given 
credit for performing model validation.  Some of this might be called “calibration” rather than “validation,” and we 
were uncertain whether it was a consistently computed measure of analytical quality. Given that model validation is 
specifically advocated by the 1996 panel recommendations, however, we included this variable in the 0-8 index. 
27 While a large number of studies score highly on the index, our index encompasses fairly minimal requirements for 
a useful analysis. The index does not take into account many other factors that contribute to a study’s quality, nor 
does it capture how well an author does the factors that are included in the index (such as sensitivity analysis and 
incremental analysis). Such additional data were not available. Nonetheless, we think the quality index does capture 
quality in a very basic sense; without these four components, few economic analyses could be considered to be of 
high analytical quality. 
28 Others, such as Chiou et al. (2003), have devised systems for appraising the quality of cost-effectiveness analyses. 
In the interest of clearly distinguishing measures of hard analytical quality (those in the zero to four index) from 
more subjective measures of quality (such as many of the variables in the zero to eight index), we wanted to design 
our own instruments for measuring quality as well as compliance with recommended protocols. 
29 There is nothing inherently better about a 3% discount rate, a societal perspective, or probabilistic sensitivity 
analysis. Nonetheless, after serious deliberation, these were the recommendations of the Panel on Cost-Effectiveness 
in Health and Medicine. Because the goal of this zero to eight index is to measure adherence to panel 
recommendations, we include these subjective recommendations in the index. To the extent that a study takes on a 
lower or higher discount rate or a different perspective, they are not adhering to recommendations.  
30 The “author’s perspective” variable is a bit problematic. Sometimes authors say they take a societal perspective 
when they do not, such as when they exclude costs that should be included in a societal perspective (such as non-
healthcare costs) and claim that they do not matter in the case at hand. In addition, there is no consensus regarding 
what, exactly, constitutes a societal perspective.  In addition to these inherent difficulties, the CEA Registry team 
changed over time, meaning that readers’ own interpretations may have changed (while the team made efforts to 
standardize results, and while the leadership of the Registry has remained constant, coding practices on this variable 
could have changed over time).         9
(Table 1).
31 Table 3 details the major categories of funding sources, affiliations, and authors’ 
perspectives available in the data.
 32 We also created three dummy variables indicating whether 
the study was conducted in the United States, other Organization for Economic Cooperation and 
Development (OECD) countries, and non-OECD countries. In order to control for journal 
quality, we added data on each journal’s annual “impact factor” over the years 1992-2001 to the 
main dataset. Figure 1 shows the relative frequencies of different years of publication, sponsors, 
affiliations, perspectives, countries, and journal impact factors. It is also important to control for 
each journal’s experience and approach to cost-effectiveness analyses. One approach would be to 
include journal fixed effects, which would control for the differential impact of each journal on 
quality. This approach, while theoretically appealing, is impractical because many journals 
appear only once in the dataset. To avoid losing a large number of observations, we instead use a 
measure of journal experience with cost-effectiveness analyses. Because the registry includes all 
cost-effectiveness analyses published in peer-reviewed health and medical journals between 
1976 and 2001, those journals appearing more frequently in the data have more experience 
publishing cost-effectiveness analyses. Journals publishing a large number of analyses may have 
editors and referees more familiar with what constitutes a high quality analysis. Thus, we would 
expect journals that publish more analyses to be more adept at reviewing them and requesting 
relevant revisions.  In fact, journals publishing and processing a large number of analyses may 
even have their own guidelines for performing cost-effectiveness analysis, or may specifically 
advocate those practices recommended by experts such as the Panel on Cost-Effectiveness in 
Health and Medicine.
33 In order to control for a journal’s experience, we measure the journal’s 
average annual output of cost-effectiveness analyses each year—based on the current and 
                                                 
31 Cost-effectiveness analyses can have multiple funding sources and, for analyses with multiple authors, multiple 
affiliations. In the dataset, most studies take only one perspective, but a small number take a government perspective 
and an NHS perspective.  Researchers on the registry team tried to assign a single perspective to most studies; as a 
result, some studies that really took two perspectives were assigned a single perspective.  For example, studies that 
took both a health care perspective and a societal perspective were categorized as “societal.” 
32 The authors’ perspective categories were designed to be exhaustive (if a perspective does not fit into a societal, 
governmental, health care sector, NHS, or unstated perspective, it is considered “other”). The five major types of 
funding (industry, government, foundation, university, and not stated) are nearly exhaustive, although there are a 
small number of studies that fit into none of these categories (for example, a very small number were funded by 
private individuals).  
33 For example, in 1996 the British Medical Journal published guidelines, in 1995 Annals of Internal Medicine 
published guidelines, in 1994 the New England Journal of Medicine published an editorial calling for higher cost-
effectiveness analysis quality, and in 1997 the Journal of the American Medical Association released a reader’s 
guide to CEA.          10
previous five years.
34 This number usually changes annually reflecting journals’ decisions to 
publish more or fewer analyses over time.
35 Figure 1 shows the relative frequencies of different 
values for the journal experience variable.   
 
4. Analysis and Results 
 
Our analysis addresses two questions. First, what affects the analytical quality of a cost-
effectiveness analysis, as measured by a quality index?  Second, did the 1996 recommendations 
of the Panel on Cost-Effectiveness in Health and Medicine affect published cost-effectiveness 
analyses?  
 
Determinants of Analytical Quality 
Equation (1) presents the general specification we used to test the effects of various 
factors on the quality of a cost-effectiveness analysis.  
 
Quality Measurei = β0 + β1*(fundingi) + β2*(affiliationi) + β3*(authors’ perspectivei) 
   + β4*(country studiedi) + β5*(journal impact factori)            
   + β6*(journal experience with CEAsi) + δ*(timei) + εi                    (1) 
 
  There are not strong a priori theoretical reasons to sign the coefficients in equation 1.  
Nonetheless, we expected that having an author take a societal perspective might improve 
                                                 
34 For example, in 1999, a journal that has published 3 total articles between 1994 and 1999 has published an 
average of 0.5 cost-effectiveness analyses per year.  The variable includes analyses published in the same year. So, 
for example, because the New England Journal of Medicine published one cost-effectiveness analysis in 1983 and 
another three between 1976 and 1982 (4 analyses over an 8-year period), the analysis published in 1983 takes on the 
value of 0.5 for the journal experience variable (average annual articles, to date). 
We assume that cost-effectiveness analyses published more than five years ago do not substantially influence a 
journal’s current level of experience with cost-effectiveness analyses. Consequently, regressions that include the 
journal experience variable can use data only from 1981 through 2001 (as 1976 was the initial year of data). While 
five years is an arbitrary amount of time, our results are robust to many other models of experience. These include 
modeling experience by the average annual number of articles published to date, measuring experience by the total 
number of articles published by the journal from 1976-2001, and measuring experience by the total number of 
articles published to date. 
35 For instance, a journal may be experienced with publishing cost-effectiveness analyses in the 1980s, have a period 
during which it published few analyses, and then become experienced again in the 2000s. Our journal experience 
variable captures the fact that experience changed. A more simplistic journal experience variable, such as the total 
number of cost-effectiveness analyses published between 1976 and 2001, would not change over time and therefore          11
quality; that studies focusing on the U.S. (and possibly other OECD countries) would be of 
higher quality;
36 that a journal’s experience with publishing cost-effectiveness analyses would 
improve quality; and that—after controlling for other factors including affiliation, funding 
source, journal experience, and journal quality—quality would improve with time. We were 
uncertain of the effect of industry funding on study quality; on the one hand, many studies find 
that industry studies are of lower quality and suffer from severe biases;
37 on the other hand, 
industry studies often enjoy generous funding budgets and have a strong economic incentive to 
follow protocols in order to improve their chances of getting published in reputable journals..   
We estimate several versions of this equation, using different dependent variables and 
different variable definitions to test the robustness of the results. In total, we use nine definitions 
of  Quality Measure. Our quality index is our principle measure of quality, but we perform 
robustness checks with eight other definitions of Quality Measure: each of the four individual 
measures of quality included in the 0-4 index; dummies for whether the study included at least 2 
of the 4 measures, at least three of the four, and all four; and the subjective (1-7) index.  
Fundingi, affiliationi, author’s perspectivei, country studiedi, journal impact factori, and 
journal experience with CEAsi  are all vectors of dummy variables indicating the relevant 
information for study i. We model time three ways to test the robustness of our results: using a 
linear time trend, a quadratic time trend, and year fixed effects.  
 
Results: Determinants of Analytical Quality 
All possible combinations of dependent variables, independent variables, and models of 
time resulted in 54 regressions—6 regressions for each dependent variable. We focus here on the 
                                                                                                                                                             
fail to capture the journal’s changing cost-effectiveness analysis publishing patterns. 
36 We suspect that on average, U.S. studies will be of higher quality than other OECD studies. Nonetheless, because 
several OECD countries (such as the United Kingdom and the Netherlands, both of which have released their own 
panel recommendations) have been strong proponents of cost-effectiveness analysis and have been among the 
leaders in cost-effectiveness analysis methodology, it is possible that OECD-country studies are of comparable 
quality to U.S. studies. Because the authors of studies outside the U.S. may have fewer resources, we expect cost-
effectiveness analyses studying non-OECD countries to generally be of the lowest quality. 
37 See Campbell et al. (2005) for a discussion of how relationships between government, universities, and industries 
have risks including misconduct, increased secrecy, and bias in the reporting of research results. Also, Angell (2004) 
expresses concerns about potential biases in industry research or industry-funded research. See also Azimi and 
Welch (1998), Friedberg et al. (1999), and Neumann et al. (2000). These studies find that industry sponsorship is 
associated with more favorable results and with what might be interpreted as biased statements on whether 
interventions are cost effective.  Hill et al. (2000), however, find “no basic intention to deceive,” although they do 
identify that sometimes “company employees had optimistic views of their product’s performance,” resulting in 
“suboptimal and poorly designed studies.”          12
results from estimating equation (1) with the quality index as the dependent variable, as it best 
captures the relevant quality measures.  The additional regressions serve as sensitivity analyses. 
Table 4 shows the results of estimating this equation using ordinary least squares.
38  None 
of the funding dummies is significantly correlated with the index, suggesting that study quality, 
measured by the quality index, does not depend on who funds the study.  This finding is 
important and supports the hypothesis that authors of industry studies are interested in following 
protocols in order to improve their chances of getting published in reputable journals. Having at 
least one author affiliated with a university is positively correlated with quality. The main 
affiliation category excluded from the model, which serves as the base group, is government 
affiliation. Thus, the results strongly suggest that university researchers produce higher quality 
cost-effectiveness analyses than government researchers. The coefficient on industry is positive 
and the coefficient on health-care affiliation is negative, but neither is statistically significant at 
conventional significance levels.  While these results suggest that industry-affiliated analyses are 
not of lower quality than analyses with other affiliations, our indicator of quality only captures 
whether researchers follow basic and recommended practices. While these are important, cost-
effectiveness analysis may be of high analytical quality according to our quality index but may 
still suffer from biases that make the results less meaningful. Furthermore, an analysis may fail 
to include some recommended protocols but nonetheless remain useful because of the 
reasonableness of its assumptions and its helpfulness to decision makers.  Our results nonetheless 
suggest that this area deserves closer scrutiny, and that authors affiliated with industry are no 
worse than other authors in following the basic, recommended practices captured by our quality 
index.
39 Cost-effectiveness analyses that focus on non-U.S. OECD countries tend to be of lower 
quality than cost-effectiveness analyses that study interventions in the United States, and 
                                                 
38 Results of these additional regressions are available upon request.  While we treat the indices as continuous 
variables and estimate regressions using them with ordinary least squares, the dependent variables in the additional 
regressions are dummy variables, thus requiring limited dependent variable regression methods.  We estimate those 
regressions with logit models.  In addition, we re-estimated the equations with probit models. There is no a priori 
reason to believe that either a logit or probit model is more appropriate, but using probit instead of logit did not 
change the results. All regressions include heteroscedasticity-robust standard errors. Although it was not practical to 
use a model with journal fixed effects, we tried using random effects. This did not change the results; coefficients as 
well as standard errors were nearly identical with those presented here. 
39 Another possible explanation for the insignificance of the coefficient on industry affiliation is that industry-
affiliated studies generally are of lower quality, but that journals set a higher standard for industry papers; that is, the 
journal may be more likely to reject an industry-funded study unless it is very high quality. This reflects an inherent 
problem with the data: we do not observe a journal’s decisions to accept or reject a paper; we only observe what a 
journal actually publishes.          13
analyses that study non-OECD countries tend to be of even lower quality. This may reflect the 
fact that researchers in non-OECD countries have fewer resources. Another possibility is, 
because the vast majority of recommended practices originated from the U.S. and other OECD 
countries, that authors of studies outside of the U.S. and OECD countries have less knowledge of 
what procedures make for a high-quality cost-effectiveness analysis.  
Having a societal perspective is positively correlated with the quality index. This result is 
statistically significant in all model specifications that use the author’s perspective, but is 
insignificant when we instead use the perspective assigned by the reader. A positive correlation 
between societal perspective and the quality index could reflect a more global view of the effects 
of a health intervention, which might necessitate a lengthier or more complete analysis.  
The quality of a cost-effectiveness analysis increases with an increase in a journal’s 
average annual output of analyses over the current and the previous five years.  We expected this 
given that a more experienced editorial staff and body of referees is likely to demand higher 
quality analyses. A journal’s impact factor is also positively correlated with the quality rating of 
a cost-effectiveness analysis published in it, but this result is not significant in all model 
specifications. 
None of the coefficients on the time dummies is significant, nor are the coefficients on 
any of the time trend variables. This result suggests that the quality of analyses has not improved 
over time, at least when we describe quality with our index.  The additional 48 regressions reveal 
that the only measure of quality that may have changed over time is whether the analysis 
discounts costs and quality adjusted life years. In all models that include a quadratic time trend, 
an analysis is more likely to discount costs and quality adjusted life years after the 1996 
recommendations than before. This result did not hold, however, when we instead used a linear 
time trend. Consequently, the results offer little support for the hypothesis that cost-effectiveness 
analyses improved on our quality index following the 1996 panel recommendations. While these 
results suggest that the 1996 panel recommendations did not affect the quality index, they may 
have affected the extent to which analyses include other panel recommendations. To better 
answer this question, we turn to our second model, which includes the components of the 
previous index in addition to a number of more subjective recommendations that we did not 
include in the quality index. 
          14
Empirical Tests: Panel Impact on Adherence to Recommended Protocols 
Equation (2) presents the general specification we used to test whether the 1996 panel 
recommendations affected the extent to which cost-effectiveness analyses follow recommended 
protocols. 
 
Compliancei = β0 + β1*(fundingi) + β2*(affiliationi) + β3* (country studiedi)  
                   + β4*(journal experience with CEAsi) + β5*(journal impact factori)                 
       + δ*(timei) + εi                            (2) 
 
We estimate several versions of equation (2), using a somewhat different set of dependent 
variables and different variable definitions to test the robustness of the results. We also model 
time in several different ways. 
Our dependent variable, Compliance,  is a measure of the extent to which a cost-
effectiveness analysis incorporates the recommendations of the Panel on Cost-Effectiveness in 
Health and Medicine. The recommendations on which we focus are the eight included in our 
panel index. In total, we use 11 definitions of Compliance: two versions of our panel index
40 and 
each of the eight individual measures of compliance included in that index.
41  
The right-hand side of equation (2) is similar to equation (1) except that it does not 
include author’s perspective
42 and we model time in a few additional ways. As in (1), we model 
time in three ways to test the robustness of our results: using a linear time trend, a quadratic time 
trend, and year fixed effects. To examine the effects of the 1996 Panel on Cost-Effectiveness in 
Health and Medicine, we also include a dummy variable for being published after the panel 
recommendations diffused. It is uncertain how quickly the recommendations diffused. This 
depends on a number of uncertain factors, including the length of time between writing a paper 
and publishing it and how quickly the panel recommendations became common knowledge.  
To test the robustness of our results to changes in the amount of time it took these 
recommendations to become common knowledge, we used three different time dummies with 
                                                 
40 One version uses the reader’s perspective and the other uses the authors’ perspective as the determinant of the 
study perspective. 
41 Societal perspective appears twice—once for the authors’ perspective being societal, and once for the reader’s 
perspective being societal. 
42 We removed author’s perspective because the panel recommended that authors take a societal perspective and this 
variable thus becomes one of our measures of quality and is incorporated into the new index.          15
each of our linear and quadratic time trends: after 1996, after 1997, and after 1998. The purpose 
of the original time trend is to de-trend the data and to test whether quality has changed over 
time. The purpose of the time dummies is to specifically test whether the panel recommendations 
had an impact on cost-effectiveness analysis quality that is different from the impact of time 
alone. By modeling time in several different ways, we rigorously test the robustness of any 
conclusions regarding the effects of time and the panel recommendations on cost-effectiveness 
analysis adherence to recommended protocols. 
Again,  fundingi,  affiliationi,  country  studiedi,  journal impact factori, and journal 
experience with CEAsi are all vectors of dummy variables indicating the relevant information for 
study i. We estimate the model with ordinary least squares when we use the panel index. All 
other models are logit models because they contain limited dependent variables.
43 
 
Results: Panel Impact on Adherence to Recommended Protocols 
All combinations of dependent variables, independent variables, and models of time 
resulted in 55 regressions—five regressions for each of the 11 dependent variables. Table 5 
shows the results of estimating equation (2) where the panel index—with author’s perspective as 
the determinant of societal perspective—serves as the dependent variable. We find some 
evidence that Compliance has improved over time, but no robust evidence that the panel 
guidelines, per se, directly affected our panel index. Time is significant at about the 1% level and 
has a positive coefficient when the equation is estimated using a linear time trend. Time is 
insignificant when we use a quadratic time trend, although this may be due to multicollinearity, 
as time and time-squared are highly correlated. Whether we assume that the panel 
recommendations diffused rapidly or slowly, we found no evidence that they had a significant 
impact on our panel index. The coefficients on the dummy for 1997, the dummy for 1998, and 
the dummy for 1999 were insignificant in all regressions. 
To explore this last result further, we estimated equation (2) with each of our multiple 
definitions of Compliance. In none of these regressions did the panel recommendations have a 
clear impact on Compliance. The result on our panel index model suggest that studies improve 
over time in some respect, but the fact that time is significant in this regression but not in the 
regressions involving the quality index suggests that improvements have occurred on the more 
                                                 
43 We also ran probit models.          16
subjective recommendations (such as using a societal perspective and a 3% discount rate) but not 
on the measures in the quality index. This result is confirmed by the additional regressions in 
which societal perspective and the dummy for having a 3% discount rate were the dependent 
variables. In these models, time was significant when we used a linear time trend, regardless of 
our assumptions about the number of years it would take the recommendations to diffuse.   
These results are not surprising. In many ways, the 1996 Panel on Cost-Effectiveness in 
Health and Medicine simply summarized and synthesized recommendations that had been 
around for some time.
44 In this case, our findings simply fail to indicate any added value of the 





Economic analysis of life-saving policy interventions has the potential to inform decision 
makers and improve the allocation of scarce public and private resources. These objectives can 
only be achieved if such analyses are done well.  
In this paper, we analyze a dataset that provides information on the content and quality of 
journal articles that measure the cost-effectiveness of life-saving investments. Our study is the 
first to provide a detailed multivariate analysis of factors affecting objective measures of quality. 
We also explore whether the recommendations by the expert panel convened by the U.S. Public 
Health Service affect the way cost-effectiveness analyses for life-saving investments are done.  
The analysis yields three key results. First, quality has not improved over time when 
measured by the quality index, but has improved over time when measured by the panel index of 
recommendations. The latter index includes subjective protocols, such as the particular discount 
rate to use and the perspective to take in conducting a study. That cost-effectiveness analyses did 
not improve on the quality index over time is somewhat surprising. Yet, it is consistent with 
other studies of government regulatory impact analyses. One possible explanation for this result 
is that our approach to measuring quality has serious limitations. For example, our results do not 
measure the extent to which study quality has improved due to more sophisticated statistical 
                                                 
44 See, e.g., Drummond et al. (1987). This is a widely-used textbook on cost-effectiveness analysis. In addition, 
other consensus groups have also released guidelines (in Canada, Australia, and later Europe).          17
approaches, enabled by the recent development of advanced statistical analysis programs and 
software packages.  
Second, it is not clear that guidelines had much effect on analytical quality.  Again, these 
results obtain both for cost-effectiveness analyses and regulatory impact analyses.
45 A critical 
question this finding raises is whether there are conditions under which guidelines are likely to 
be more effective in improving analysis. In the federal government, we think that it is critical to 
have an enforcement mechanism. In the case of peer-reviewed work, the enforcement 
mechanism is less clear if referees and editors do not require it. 
The third result, which was something of a surprise, relates to the impact of funding 
sources. We found that the source of study funding is not significantly correlated with the quality 
of cost-effectiveness analyses as measured by the quality index. One possible explanation for our 
results is that it was not intended to pick up subtle forms of bias, yet we still think it has 
relevance because it shows that on some general objective measure of quality, funding does not 
appear to make a difference. There is an important ongoing debate in the literature about 
conflicts of interest, the effect of disclosure, and the impact of funding sources. Our result should 
be considered in conjunction with other findings in devising sensible policies related to possible 
conflicts of interest. 
Social and private life-saving interventions represent a significant economic investment. 
Moreover, they are likely to become more important in magnitude as the demand for health-
related services and their costs increase. We need to learn more about the factors that drive this 
investment, including any underlying analysis, if we wish to substantially improve it. 
                                                 
45 Hahn and Dudley (2004) show that these results obtain for regulatory impact analyses.           18
Table 1: Definition of Variables 
Variable Meaning 
Research sponsor  This is the source of funding of the research carried out by the authors of the cost-
effectiveness analysis.  
Authors' affiliation 
Author's affiliation indicates the authors' primary association or membership when 
the paper was written. Where a single paper has multiple affiliations, some of the 
authors had one affiliation (e.g., university) while other author(s) had another (e.g., 
government). The data do not indicate the affiliation of the primary author, so we 
only know that one or more authors have the listed affiliation(s) (not which ones). 
Authors' perspective 
Author's perspective indicates the perspective from which the authors calculate 
costs and benefits. If the perspective is governmental, the analysis addresses how 
much something would cost the government (e.g., the cost of a proposed law for 
the government). A health care perspective looks at the costs that face HMOs, 
hospitals, etc. A patient’s perspective looks at patient costs (e.g., the cost of a 
procedure and the amount of time the patient is unable to work). When authors 
take a societal perspective, they consider "everyone affected by the intervention, 
and all health effects and costs that flow from it are counted, regardless of who 
would experience them" (Russell et al. 1996). Authors declare their perspective. 
Reader's perspective  According to the registry team, sometimes an author would claim to have one 
perspective, but it appeared to the reader (a member of the registry team) that 
they had another. As a result, the researchers created two perspective variables: 
the author’s perspective and the reader’s perspective. 
Country of Study 
This is the country on which the study is based. In some cases, this is a region 
(such as sub-Saharan Africa or Western Europe) but usually it is a single country. 
All analyses fit into one of three categories: U.S., non-U.S. Organization for 
Economic Cooperation and Development (OECD), and non-OECD studies. 
Model Validation 
Model validation is generously characterized. If the author compared modeling 
projections for disease progression to actual data (empirical work), contrasted 
results from different models, or even “discussed” model validation, the registry 
team credited the analysis with including model validation.  In some cases, a 
study’s "model validation" might be more appropriately called “calibration.” 
Discount Rate 
The discount rate is the interest rate at which the authors discount future events. A 
present-oriented author discounts the future heavily, using a high discount rate. 
Journal Impact Factor  A measure used to rank the importance of scientific journals. It is a measure of the 
frequency with which the “average article” in a journal has been cited in a 
particular year or period. Generally, the higher the impact factor, the higher the 
“impact” (i.e. “quality” or “prestige”) of the journal. 
Average analyses, 
current and previous 5 
years 
This is a number indicating the average annual number of CEAs published by the 
journal during the current and previous 5 years. It is a measure of journal 
experience with publishing CEAs. The higher this value, the more experienced. 
Incremental Analysis  The difference in the cost of two different courses of action is compared to their 
difference in outcomes by dividing the former by the latter.  This ratio is known as 
the incremental cost-effectiveness ratio.          19
Sensitivity Analysis  Sensitivity analysis is a procedure used to ascertain how closely a given model 
output depends upon the input parameters. Authors do this by varying model input 
parameters over a reasonable range and observing the relative changes in model 
response. If a small change in a parameter results in relatively large changes in 
the outcomes, the outcomes are said to be sensitive to that parameter. This may 
mean that the parameter has to be determined very accurately or that the 
alternative has to be redesigned for low sensitivity.  
Probabilistic Sensitivity 
Analysis 
Probabilistic sensitivity analysis is a type of sensitivity analysis for which outputs 
are calculated based on random assignment of values to inputs (drawn from a 
user-selected probability distribution). 
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Table 2  
Means, All Dependent Variables 
Variable Mean  Standard 
Deviation
 Subjective Reader Rating (0-7)  4.2  1.3 
 Number of quality measures that =1 for the analysis (0-4)  3.2  0.94 
 Number of quality measures that =1 for the analysis (0-8), using authors’ perspective  4.2  1.6 
 Number of quality measures that =1 for the analysis (0-8), using reader's perspective  4.1  1.5 
 Dummy - Incremental analysis performed (included in 0-4 and 0-8 indices)  0.9  0.30 
 Dummy - Discounts costs and quality adjusted life years (included in 0-4 and 0-8 indices)  0.81  0.39 
 Dummy - Year of currency for cost estimates stated (included in 0-4 and 0-8 indices)  0.76  0.43 
 Dummy - Sensitivity analyses performed (included in 0-4 and 0-8 indices)  0.91  0.28 
 Dummy - analysis meets at least 2 of the quality measures in the 0-4 index  0.93  0.25 
 Dummy - analysis meets at least 3 of the quality measures in the 0-4 index  0.81  0.40 
 Dummy - analysis meets all 4 of the quality measures in the 0-4 index  0.49  0.50 
 Dummy - Probabilistic Sensitivity Analysis performed (included in 0-8 index)  0.086  0.28 
 Dummy - Model Validation (included in 0-8 index)  0.15  0.35 
 Dummy - 3% discount rate (included in 0-8 index)  0.36  0.48 
 Dummy - Societal perspective (authors’) (included in 0-8 index)  0.39  0.49 
 Dummy - Societal perspective (reader's) (included in 0-8 index)  0.27  0.45 
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Table 3 
Most Common Funding Sources, Affiliations, and Author 
Perspectives 
Funding Source  Authors' Affiliation  Authors' Perspective 
Industry Industry  Societal 
Government Government  Government 
Foundation University  Health  care  sector 
University  Health care organization  National Health Service 
Not stated  Consultant/ contracted researcher Not stated 
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Figure 1 
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Table 4: Determinants of Analytical Quality, Ordinary Least Squares 
Regression Results 
        
 Dependent Variable: Quality Index (0-4)  (1)  (2)  (3)  (4)  (5)  (6) 
 Industry funding  -0.161  -0.177  -0.176  -0.173  -0.187  -0.187 
    (1.16)  (1.29)  (1.28) (1.25) (1.38)  (1.37) 
 Government funding  0.110  0.099  0.094  0.071  0.067  0.059 
    (0.92)  (0.84)  (0.79) (0.60) (0.56)  (0.50) 
 University funding  0.106  0.076  0.080  0.154  0.147  0.151 
    (0.60)  (0.45)  (0.48) (0.66) (0.64)  (0.67) 
 Foundation/ society funding  0.093  0.088  0.082  0.119  0.121  0.114 
    (0.85)  (0.81)  (0.75) (1.09) (1.10)  (1.03) 
 Undetermined funding source  -0.013  -0.010  -0.012  -0.038  -0.033  -0.036 
    (0.10)  (0.07)  (0.08) (0.28) (0.24)  (0.26) 
 Author's perspective is societal  0.353  0.357  0.355        
   (3.37)**  (3.43)**  (3.40)**          
 Author's perspective is government  0.070  0.107  0.076        
   (0.16)  (0.25)  (0.17)          
 Author's perspective is the NHS  0.410  0.366  0.387        
   (1.14)  (1.04)  (1.08)          
 Author's perspective is the health-care sector  0.197  0.173  0.176        
   (1.28)  (1.15)  (1.17)          
 Author's perspective is "other"  -0.152  -0.139  -0.140        
   (0.83)  (0.77)  (0.78)          
 Reader's perspective is societal        0.295  0.417  0.399 
            (0.70)  (1.00)  (0.94) 
 Reader's perspective is government        0.354  0.448  0.422 
            (1.32)  (1.72)+  (1.61) 
 Reader's perspective is the NHS        0.253  0.276  0.278 
            (0.57)  (0.62)  (0.62) 
 Reader's perspective is the health-care sector        0.215  0.339  0.323 
            (0.52)  (0.82)  (0.76) 
 Reader's perspective is OTHER        -0.401  -0.270  -0.302 
            (0.89)  (0.61)  (0.67) 
  University-affiliated  0.336  0.341  0.344 0.325 0.317  0.323 
    (1.79)+  (1.80)+  (1.81)+ (1.76)+ (1.72)+  (1.74)+ 
 Industry-affiliated (includes consultants/ contractors)  0.156  0.157  0.156  0.170  0.170  0.169 
    (1.15)  (1.17)  (1.17) (1.24) (1.26)  (1.26) 
 Health care organization-affiliated  -0.087  -0.113  -0.109  -0.079  -0.098  -0.093 
    (0.70)  (0.95)  (0.91) (0.63) (0.81)  (0.77) 
 Non-U.S. OECD country studied  -0.277  -0.278  -0.279  -0.329  -0.319  -0.322 
    (2.71)**  (2.70)**  (2.71)** (3.06)** (2.94)**  (2.96)** 
 Non-OECD country studied  -0.845  -0.847  -0.852  -0.876  -0.869  -0.878 
   (1.92)+  (1.96)+  (1.93)+  (2.08)*  (2.08)*  (2.06)* 
 Journal Impact Factor  0.017  0.014  0.014  0.020  0.018  0.018 
   (1.59)  (1.42)  (1.39)  (1.98)*  (1.85)+  (1.81)+ 
Analyses published, current and past 5 years  0.121  0.131  0.133  0.132  0.140  0.142 
    (3.57)**  (3.98)**  (4.04)** (3.85)** (4.20)**  (4.26)** 
 Time trend    -0.008  -0.362    0.013  -0.409 
      (0.25)  (1.00)     (0.40)  (1.09) 
 Time trend, squared      0.008      0.009 
         (0.98)        (1.14) 
 Analysis was published in 1997 or after    0.130  0.209    0.084  0.180 
      (0.70)  (1.01)     (0.45)  (0.84) 
  Constant  3.188  2.789  6.798 3.002 2.202  6.999          25
   (8.52)**  (4.15)**  (1.64)  (5.31)**  (2.61)**  (1.58) 
  Observations  431  431  431 431 431  431 
  R-squared  0.21  0.20  0.20 0.20 0.19  0.19 
 Absolute value of t statistics in parentheses 
+ significant at 10%; * significant at 5%; ** significant at 1% 
All regressions include heteroscedasticity-robust standard errors 
All models that do not include a time trend were estimated with 
year fixed effects. 
Note: The 0-4 index includes: performing incremental analysis, 
discounting costs and quality adjusted life years, stating the year 
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Table 5: Panel Impact on Compliance with Panel Recommendations,  
Ordinary Least Squares Regression Results 
     
Dependent Variable: Panel Index (0-8)  (1) (2) (3)  (4)  (5)  (6) (7) 
 Industry funding  -0.105  -0.152  -0.156  -0.133  -0.132  -0.154  -0.161 
   (0.46)  (0.68)  (0.69)  (0.59)  (0.58)  (0.70)  (0.72) 
 Government funding  0.290  0.238  0.233  0.260  0.249  0.240  0.227 
   (1.48)  (1.21)  (1.17)  (1.32)  (1.25)  (1.24)  (1.16) 
 University funding  0.174  0.096  0.089  0.103  0.111  0.095  0.090 
   (0.30)  (0.17)  (0.16)  (0.17)  (0.19)  (0.16)  (0.15) 
 Foundation/ society funding  0.117  0.119  0.115  0.128  0.115  0.133  0.124 
   (0.62)  (0.64)  (0.61)  (0.68)  (0.61)  (0.71)  (0.66) 
 Undetermined funding source  0.046  0.059  0.054  0.051  0.049  0.042  0.039 
   (0.21)  (0.26)  (0.24)  (0.23)  (0.22)  (0.19)  (0.18) 
 University-affiliated  0.106  0.123  0.122  0.098  0.105  0.117  0.124 
   (0.41)  (0.46)  (0.46)  (0.38)  (0.40)  (0.45)  (0.47) 
 Industry-affiliated (includes consultants/ contractors)  0.045  0.066  0.066  0.045  0.043  0.068  0.073 
   (0.20)  (0.28)  (0.28)  (0.19)  (0.19)  (0.29)  (0.31) 
 Health care organization-affiliated  -0.286  -0.283  -0.280  -0.307  -0.298  -0.264  -0.254 
   (1.48)  (1.50)  (1.47)  (1.60)  (1.55)  (1.39)  (1.33) 
 Non-U.S. OECD country studied  -0.715  -0.751  -0.754  -0.745  -0.746  -0.760  -0.764 
   (4.69)**  (4.92)**  (4.93)** (4.89)**  (4.91)**  (5.02)** (5.06)** 
 Non-OECD country studied  -1.054  -1.140  -1.142  -1.083  -1.100  -1.106  -1.127 
   (1.21)  (1.31)  (1.31)  (1.25)  (1.25)  (1.30)  (1.30) 
 Journal Impact Factor  0.068  0.066  0.066  0.065  0.064  0.067  0.067 
   (4.05)**  (3.90)**  (3.89)** (3.86)**  (3.81)**  (4.03)** (4.01)** 
 Average analyses published, current and past 5 years  0.333  0.357  0.358  0.357  0.360  0.349  0.350 
   (4.99)**  (5.32)**  (5.31)** (5.37)**  (5.36)**  (5.20)** (5.19)** 
 Time trend     0.213  0.016  0.158  -0.546  0.123  -0.231 
      (5.08)**  (0.03)  (3.19)**  (1.14)  (2.47)*  (0.51) 
 Time trend, squared      0.004    0.015    0.008 
       (0.30)    (1.45)    (0.76) 
Analysis was published in 1996 or after     -0.200  -0.136             
      (0.79)  (0.40)             
Analysis was published in 1997 or after        0.206  0.361      
         (0.78)  (1.33)      
Analysis was published in 1998 or after                 0.376  0.373 
                  (1.50)  (1.49) 
 Constant  3.291  -0.897  1.335  0.073  8.049  0.786  4.716 
   (6.02)**  (0.98)  (0.18)  (0.07)  (1.51)  (0.75)  (0.94) 
 Observations  431  431  431  431  431  431  431 
 R-squared  0.35  0.34  0.34  0.34  0.34  0.34  0.34 
Absolute value of t statistics in parentheses 
All models that do not include a time trend were estimated with 
year fixed effects. 
All standard errors are robust to heteroscedasticity. 
+ significant at 10%; * significant at 5%; ** significant at 1% 
Note: The 0-8 index includes the variables in the 0-4 index plus 
performing probabilistic sensitivity analysis, model validation, using a 
3% discount rate, and taking a societal perspective (author's 
perspective).   27
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